The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Updated analysis of MAIA: D-Rd continues to beat Rd in transplant-ineligible NDMM
Nizar Bahlis, MD, University of Calgary, Calgary, AB, Canada, gives an update on the MAIA trial (NCT02252172), which compared the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (MM) who are not candidates for high dose chemotherapy and autologous stem cell transplant. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
